flutamide has been researched along with mdv 3100 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, S; Fujii, S; Fujimoto, N; Gouda, H; Hu, D; Iguchi, K; Ikari, A; Irie, K; Kawai, M; Matsukawa, T; Matsunaga, T; Nakayama, T; Oguri, H; Okada, T; Segawa, J; Toyooka, N; Xia, S | 1 |
| Bignan, G; Bischoff, JR; Branch, JR; Bush, TL; Connolly, PJ; Hickson, I; Lim, HK; Meerpoel, L; Ondrus, J; Pande, V; Rocaboy, C; Trabalón Escolar, L; Zhang, Z | 1 |
| Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F | 1 |
| Culig, Z | 1 |
| Dagvadorj, A; Ellsworth, E; Gu, L; Gupta, S; Hoang, DT; Koptyra, M; Leiby, B; Liao, Z; Merry, DE; Mirtti, T; Montie, H; Nevalainen, MT; Savolainen, S; Shen, F; Talati, PG; Tan, SH | 1 |
| Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P | 1 |
| Awrey, S; Azad, AA; Cherkasov, A; Chi, KN; Collins, CC; Gleave, ME; Lallous, N; LeBihan, S; Leblanc, E; Murillo, J; Rennie, PS; Singh, K; Tse, R; Volik, SV; Wyatt, AW | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| El-Shishtawy, KA; Ide, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Reis, LO; Zheng, Y | 1 |
| Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N | 1 |
| Hamada, K; Iguchi, T; Kato, M; Nakatani, T; Otoshi, T; Tamada, S; Yamasaki, T; Yasuda, S | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Tamada, S; Yamasaki, T; Yasuda, S | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Morizane, S; Sejima, T; Takenaka, A; Yamaguchi, N; Yumioka, T | 1 |
| Adachi, T; Deguchi, T; Harimoto, K; Hase, T; Iguchi, T; Ishii, K; Iwamoto, K; Iwata, H; Kanamaru, T; Kato, M; Machida, Y; Morimoto, K; Nakatani, T; Ohmachi, T; Takegaki, Y; Tamada, S; Tashiro, K; Yamamoto, S; Yasuda, S | 1 |
| Akamatsu, S; Fujimoto, Y; Inoue, T; Kimura, T; Kobayashi, T; Matsubara, N; Mori, K; Murakami, K; Ogawa, O; Terada, N | 1 |
| Asakawa, K; Hinotsu, S; Horie, S; Kakehi, Y; Kobayashi, K; Naito, S; Nonomura, N; Ogawa, O; Oya, M; Saito, A; Suzuki, K; Uemura, H; Uno, S; Yokomizo, A | 1 |
3 review(s) available for flutamide and mdv 3100
| Article | Year |
|---|---|
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms | 2013 |
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds | 2014 |
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome | 2015 |
2 trial(s) available for flutamide and mdv 3100
| Article | Year |
|---|---|
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Protocols; Flutamide; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Research Design; Retreatment | 2019 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome | 2020 |
12 other study(ies) available for flutamide and mdv 3100
| Article | Year |
|---|---|
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2020 |
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
Topics: | 2021 |
Enzalutamide shows strong activity in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Flutamide; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2014 |
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Signal Transduction; STAT5 Transcription Factor; Tosyl Compounds; Tumor Suppressor Proteins | 2015 |
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High-Throughput Nucleotide Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2016 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Down-Regulation; Flutamide; Humans; Interleukin-6; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA; Tosyl Compounds; Transcription, Genetic; Urinary Bladder Neoplasms | 2016 |
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2018 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Flutamide; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2019 |
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2020 |
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
Topics: Androgen Antagonists; Androgens; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2022 |